This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Androgen insensitivity syndrome: do trinucleotide repeats in
androgen receptor gene have any role?
Singh Rajender1,3, Nalini J.
Gupta2, Baidyanath
Chakravarty2, Lalji Singh1, Kumarasamy
Thangaraj1
1Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad 500007, India
2Institute of Reproductive Medicine, Salt Lake, Kolkata PN 700064, India
3Division of Endocrinology, Central Drug Research Institute, Lucknow, India
Abstract
Aim: To investigate the role of CAG and GGN repeats as genetic background affecting androgen insensitivity
syndrome (AIS) phenotype. Methods: We analyzed lengths
of androgen receptor (AR)-CAG and GGN repeats in 69 AIS
cases, along with 136 unrelated normal male individuals. The lengths of repeats were analyzed using polymerase
chain reaction (PCR) amplification followed by allelic genotyping to determine allele length.
Results: Our study revealed significantly shorter mean lengths of CAG repeats in patients (mean 18.25 repeats, range 14_26 repeats) in
comparison to the controls (mean 22.57 repeats, range 12_39 repeats) (two-tailed
P < 0.0001). GGN repeats, however, did not differ significantly between patients (mean 21.48 repeats) and controls (mean 21.21 repeats)
(two-tailed P = 0.474). Among patients' groups, the mean number of CAG repeats in partial androgen insensitivity cases
(mean 15.83 repeats) was significantly less than in complete androgen insensitivity cases (mean 19.46 repeats)
(two-tailed
P < 0.0001).
Conclusion: The findings suggest that shorter lengths of repeats in the AR gene might act as low
penetrance genetic background in varying manifestation of androgen
insensitivity. (Asian J Androl 2008 Jul; 10: 616_624)
Keywords: androgen receptor; CAG repeat; GGN repeat; androgen insensitivity
Correspondence to: Dr Kumarasamy Thangaraj, Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad 500007, India.
Tel: +91-40-2719-2636 Fax: +91-40-2716-0591
E-mail: thangs@ccmb.res.in
Received 2006-10-10 Accepted 2007-07-23
DOI: 10.1111/j.1745-7262.2007.00337.x
1 Introduction
Androgens (testosterone and dihydrotestosterone)
mediate their functions through androgen receptors (AR).
The end organ resistance to androgens manifest in a
spectrum of androgen insensitivity syndromes (AIS), with
mild form AIS (MAIS) represented by male infertility or
undermasculinization, partial form AIS (PAIS) represented
by ambiguous genitalia and complete form AIS (CAIS)
represented by female phenotype in genetically male
individuals [1]. Mutations in the AR gene are a frequent
cause of AIS; however, the origin of certain other cases
remains elusive [2, 3]. The genotype_phenotype
correlations in AIS had been very enigmatic. Same nucleotide
substitutions in the AR gene have been reported in
different grades of AIS [4] (see
www.androgendb.mcgill.ca/). G2445A substitution is known to cause both PAIS
[5] and CAIS [6]. C2296A substitution, with proven
pathogenicity in PAIS [7] and CAIS [8] patients, was
also observed in an absolutely normal individual [9].
Another interesting example is G995A mutation, which is
known to cause MAIS [10], PAIS [11] and CAIS [11],
and has also been reported to exist in 8% of the normal
population [12].
Some studies propose the role of `genetic background' or `modifiers', in varying manifestation of AIS
[13_15]. The mutations/polymorphisms in the genes
involved in androgen action might affect overall response
to androgens. The somatic mutations in androgen
responsive organs have been reported to account for
phenotypic variations in some cases [14, 15]. The exposure
of the fetus to androgens at embryonic stage has also
been suggested to count for the variations [16]. Holterhus
et al. [16] report a family with four affected individuals
sharing the same mutation in the AR gene but having
different phenotypes. On the basis of the response to
testosterone, it was concluded that variation in the
phenotype was the result of variation in ligand concentration
in early fetal life. In a similar study, Boehmer
et al. [17] reported that variation in the phenotype in affected
individuals might vary depending on 5-α reductase 2
activities. However, the above factors have been able to
explain only few cases out of more than 20 known cases
of phenotypic variations.
The AR gene has two polymorphic (CAG and GGN) repeats in exon 1, encoding variable lengths of
polyglutamine and polyglycine stretches, respectively, in the
N-terminal region of the protein. CAG, a simple
repeat, varies in length from 8 to 35 repeats, whereas GGN, a
complex repeat, represented by
(GGT)3GGG(GGT)2(GGC)n
, varies in length from 10 to 30 repeats. Variations in lengths of CAG repeats have been associated
with diverse clinical conditions [18]. These studies along
with in vitro assays have shown an inverse correlation
between CAG repeat length and AR transactivation
function [19, 20]. However, GGN repeat length variation
has been relatively less studied, therefore, more studies
are required to reach conclusions about the association
of repeat length variation with AR function. Taking into
consideration the functional proof of inverse correlation
of lengths of CAG repeats with AR function, we
undertook the present study on AR-CAG and GGN repeats to
determine whether variations in the length of these
repeats was associated with phenotypic variations in AIS.
2 Materials and methods
2.1 Subjects and clinical evaluation
A total of 69 AIS cases were recruited through the
Institute of Reproductive Medicine (IRM), Kolkata, India.
The patients belonged to Indo-European and
Austro-Asiatic linguistic affiliations and were inhabitants of four
states (West Bengal, Orissa, Bihar and Jharkhand) of
India. All the patients were subjected to physical and
clinical evaluations, and family histories of all the patients
were recorded. Upon complete clinical examination,
phenotypes were diagnosed as PAIS in 23 patients and as
CAIS in the remaining 46 (Table 1).
The assignment of androgen insensitivity was based
upon the presence of 46, XY karyotpye, abdominal
gonads and testicular tissue in gonads (histology done
wherever possible). Patients were further classified as PAIS
and CAIS categories on the basis of individual phenotype.
Serum levels of testosterone, leutinizing hormone (LH)
and follicle stimulating hormone (FSH) were measured
by radioimmunoassay. Absolute values of testosterone
and LH were multiplied to obtain androgen sensitivity
index (ASI) values. Out of a total of 69 patients, 52
underwent surgical extraction of gonads, biopsy from
which was used for histopathological analyses. At least
57 patients had a first-degree or second-degree relative
with AIS phenotype. Although we could not collect samples
of the siblings for all cases, we had samples of two
siblings from three families and three siblings from one
family. However, phenotype was the same in two or
more affected siblings from these two families. A total
of 136 healthy, unrelated and ethnically matched fertile
men with no symptoms of undervirilization were recruited
in the study as controls. Blood samples from the
patients and controls were collected with their fully informed
written consent.
In addition to the above patients and controls, we
also analyzed repeat length data available on AR mutation
database (www.androgendb.mcgill.ca/). Information
regarding CAG and GGN repeat length is available in the
database for a significant number of cases. These cases
represent patients from different populations of the world,
which therefore serves as a stringent dataset to validate
our results. We selected this as a third dataset to cross
check our findings of differences between PAIS and CAIS
cases. For this purpose, all the mutations resulting in
amino acid substitutions were taken into account but not
the mutations resulting in reduction of AR expression or
truncation of AR protein.
2.2 CAG and GGN repeat length analysis
DNA was isolated from peripheral blood lymphocytes
using protocol described in our earlier study [21]. CAG
repeat region of the AR gene was amplified with a pair of
primers, forward: 5'-FAM-CAGAATCTGTTCCAGAGCGTGC-3', reverse:
5'-AAGGTTGCTGTTCCTCATCCAG-3' flanking the repeat. Polymerase chain reaction
(PCR) mixture consisted of 1.0 μL PCR buffer (10 ×),
1.0 μL MgCl2 (25 mmol/L),
1.0 μL dNTPs (10 mmol/L), 1.0 pmol/L of each primer, 0.5 units Amplitaq Gold DNA
polymerase and 20 ng genomic DNA. PCR was
performed under the following conditions: initial
denaturation at 94ºC for 12 min followed by 30 cycles of 94ºC
for 1 min, 55ºC for 1 min and 72ºC for 1 min, with a
final extension at 72ºC for 30 min. GGN repeat was
amplified with a pair of primers: forward 5'-FAM-CCGCTTCCTCATCCTGGCACAC-3' and reverse
5'-GCCGCCAGGGTACCACACATC-3' flanking the repeat region. PCR reaction mixture included
1.0 μL PCR buffer (10 ×), 1.0 μL
MgCl2 (25 mmol/L), 1.0 μL dNTPs
(10 mmol/L), 1.0 μL DMSO (100%),
1.0 μL glycerol (100%), 1.0 pmol/L of each primer, 0.5 units Amplitaq
Gold DNA polymerase and 20 ng genomic DNA. PCR
conditions consisted of denaturation at 96ºC for
15 minutes, followed by 40 cycles at 96ºC for 1.5 min,
65ºC for 1 min and 72ºC for 3 min and a final
extension at 72ºC for 20 min. For GeneScan,
3.0 μL of PCR product was mixed with
0.2 μL of LIZ500 and 6.8 μL Hi-Di formamide. Upon denaturation for 5 min at 95ºC and
cooling for 5 min on ice, samples were run on 3730 DNA
analyzer (Applied Biosystems, Foster City, CA, USA).
PCR and genotyping were repeated for all samples to
confirm the number of the repeats. The raw data were
further analyzed using GeneMapper software (Applied
Biosystems).
2.3 Statistical analysis
Mean, median and mode were calculated as
descriptive statistics using spss software (version 11, SPSS,
Chicago, IL, USA). Initially, the difference in mean
repeat length for cases and controls was estimated to
obtain overall difference between the two. Later the
patients were categorized in two groups (CAIS and PAIS)
and repeat data was compared between these groups.
The significance of the differences in mean repeat length
was tested by independent samples t-test using
spss software. Only two-tailed P-values were used for
acceptance or rejection of null hypotheses and
P < 0.05 were considered significant. For joint analysis, the
numbers of CAG and GGN repeats were cross-classified in
three groups of less than average, average and more than
average repeat length to observe the differences between
cases and controls.
To understand the relationship between various
clinical and genetic factors, we analyzed the data for Pearson
correlation. To explore the possibility of various clinical
and genetic parameters to be used as diagnostic factors
for discrimination between CAIS and PAIS phenotype,
we created receiver's operating characteristic (ROC)
curves. For ROC curves, the phenotype (CAIS or PAIS)
was taken as the state variable while CAG and GGN
repeats length; testosterone, LH and FSH level were taken
as predicting parameters. To understand the relationship
between the phenotype and clinical parameters, we
further analyzed the data by regression. For regression
analyses, phenotype (CAIS or PAIS) was taken as the
dependent parameter and various clinical and genetic
factors as independent parameters.
3 Results
3.1 Clinical evaluation
Measurements of serum hormone levels showed that
testosterone, LH and FSH levels were in the upper
normal male range in the majority of the cases, and LH and
FSH values were very high in some cases (Table 1).
Testosterone and LH were elevated in almost 50% of CAIS
cases and 40% of PAIS cases. In total, testosterone and
LH levels were elevated in approximately 90% of the
cases. In contrast, FSH levels were elevated in
approximately 10% of the cases. Among all the cases, ASI was
elevated in approximately 50%; however, it was in the
upper normal male range in more than 90% of cases.
Histopathology of testicular biopsies indicated testicular
cancers or hyperplasia of interstitial or Sertoli cells in 52
(75.36%) cases [22].
3.2 Genetic analyses
We observed narrowed CAG repeat length range in
patients (14_26 repeats) as compared to controls
(12_39 repeats) (Figure 1). Additionally, the mean number
of the repeats was statistically significantly less in
patients (18.25 repeats) in comparison to the controls (22.57
repeats) at the 95% confidence level (P < 0.0001). The
modal value of CAG repeats was lower for the patients
(15 and 19 repeats) than for the controls (23 repeats).
Among patients groups, PAIS cases had significantly
smaller mean CAG repeat length (15.83 repeats) in
comparison to CAIS cases (19.46 repeats) at the 95% level
of confidence (P < 0.0001) (Table 2). All PAIS cases
had ¡Ü 23 CAG repeats (assuming 22 and 23 repeats as
maximum frequent or average number of repeats), whereas CAIS cases had a normal distribution of CAG
repeats. In familial cases, all affected siblings had a similar
phenotype, however the CAG repeat length did not
differ significantly among these individuals.
In contrast, GGN repeat was less polymorphic and
mean repeats length did not differ significantly between
patients (mean length 21.48 repeats) and control groups
(mean length 21.21 repeats) (Table 3). Alleles with 21
and 22 repeats were most frequent with a very low
frequency of other alleles on either side of the average
(Figure 2). AR alleles with 17 GGN repeats were
observed only in the patients. Mean number of GGN
repeats length did not differ significantly between PAIS
(21.43 repeats) and CAIS (21.50 repeats) categories.
Modal value of this repeat was the same (22 repeats) in
PAIS, CAIS and control individuals (Table 3). Joint
distribution analysis of CAG/GGN repeats length showed
significant differences in the distribution of these repeats
in various combinations between cases and controls
(Table 4).
Comparison of repeat length variation for the data
from AR mutation database revealed that 77% of PAIS
cases had ¡Ü 23 repeats, whereas only 23% had more
than 23 repeats and only 2 (6.67%) out of a total 30
cases had more than 25 repeats (Figure 1). Among both
CAIS and MAIS cases, almost an equal number of
individuals had repeats below and above average. The mean
number of repeats in PAIS cases (20.63 repeats) was
statistically significantly less than for CAIS cases (23.12
repeats) at the 95% level of confidence (P = 0.01)
(Table 2). CAG repeat in CAIS did not show the
expected normal distribution, probably because this data
was constituted by samples from different ethnic
populations. Unfortunately, CAG repeat information was not
available for all the cases annotated in the AR mutation
database, which would have given a much clearer
picture about the relationship between number of repeats
and AIS phenotype. This shows the importance of
analyzing CAG repeats length in studies involving the AR
gene.
Significant correlations were observed between
phenotypes (CAIS or PAIS), CAG repeat length (r
= 0.661, P = 0.000) and FSH and LH levels
(r = 0.27, P = 0.025)
(Table 5). However, CAG and GGN repeat lengths did
not correlate significantly each other. ROC curve
analysis indicates that CAG repeat length is the best
diagnostic factor to differentiate between CAIS and PAIS
(Figure 3) (Table 6). Length variation of CAG repeats
could account for 91.2% variability in AIS phenotype (area
under the curve = 0.912, P = 0.000). Although ratio of
CAG and GGN repeat length could also be used for
diagnosis (area under the curve = 0.857,
P = 0.000), it could be attributed to CAG repeat only because the GGN
repeat did not correlate significantly with the AIS
phenotype (Table 6). For diagnostic purposes aimed at
discrimination between CAIS and PAIS, the best cut-off value
for CAG repeat was 17.5 repeats, whereas the best
cut-off for CAG/GGN ratio was 0.85. The remaining
parameters were not significant for diagnostic purposes.
Regression analysis revealed that the best predicting factor
for AIS phenotype was CAG repeat length
(R2 = 0.455). The variation in AIS phenotype could be largely
attributed to CAG repeat length polymorphisms (standardized
regression coefficient, β = 0.656) (Table 7), whereas
other factors did not account significantly for variability
in AIS phenotype.
4 Discussion
In the present study, we have analyzed CAG and GGN repeat length polymorphisms in the AR gene, to
observe the role of these repeats as genetic modifiers of
androgen insensitivity. Considering the differences
observed between PAIS and CAIS cases, we hypothesize
that one major component of genetic background in manifestation of AIS is constituted by CAG repeat of the
AR gene. Molecular defects that disrupt androgen
binding completely are likely to result in CAIS irrespective of
number of CAG repeats in the AR gene. However,
eventual level of androgen insensitivity in the cases with
molecular defects resulting in partial loss of androgen
binding or transactivation potential might be affected by the
number of CAG repeats in the AR gene. The presence
of shorter/less than average number of CAG repeats might
compensate partially for loss of androgen sensitivity,
whereas the presence of more than average number of
repeats might enunciate the extent of androgen
insensitivity. Therefore, molecular defects resulting in partial
loss of sensitivity to androgens might manifest as PAIS
when presented in combination with equal to or less
than average number of CAG repeats, but as CAIS when presented with more than average number of this
repeat. It is possible that a longer CAG repeat might
give rise to MAIS with or without other contributing
factors. Molecular defects having mild effects on
androgen sensitivity, when presented in combination with
very few CAG repeats (much less than average) in the
AR gene might not be pathogenic at all. The finding of
relatively shorter repeats in PAIS in comparison to CAIS
cases from the AR mutation database validated out hypothesis.
More than 70 different proteins have been identified
as interacting with AR for its downstream action (see
www.androgendb.mcgill.ca/). The polyglutamine tract
is located in the region of the AR protein known to
interact with some AR coregulators. Transfection assays
have demonstrated that interaction of AR with coactivator
ARA24 decreases with increasing AR-CAG repeat length,
resulting in decreased AR transactivation potential.
Similarly, longer lengths of CAG repeats result in
decreased ability of AR to be activated by members of the
steroid receptor coactivators (SRC) family of
coregulators (SRC-1, SRC-3 and transcriptional intermediary
factor (TIF-2) [23]. The above factors indicate that length
of CAG repeats is crucial for AR action and might affect
androgen action. AR is also known to interact with many
tumor suppressor genes [23]; however, the influence of
CAG repeat on the interaction of AR with these genes is
yet to be deciphered. Therefore, in addition to
polymorphic variations in AR gene, polymorphisms in AR
interacting genes or in promoter regions of AR target genes
might influence overall transactivation potential of AR
gene and, hence, sensitivity to androgens. In contrast,
GGN repeat does not seem to affect the level of
androgen insensitivity. Although joint analyses of the two
repeats (haplotypes) showed certain differences between
cases and controls, they were not statistically significant
and could be attributed mainly to CAG repeat
distribution and the smaller sample size of the cases in
comparison to controls. ROC curves and regression analyses
also showed that the majority of variations in AIS
phenotype could be attributed to CAG repeat length with minor
contribution from other factors.
The levels of testosterone, LH and their
multiplication product (ASI) were elevated in approximately 50%
of the cases; however, more than 90% of the cases had
ASI levels in the upper male range. This indicates that
ASI values in the upper normal male range or higher than
that might indicate AIS in an individual. The analysis of
CAG repeats length among siblings sharing the
molecular defect but displaying different phenotypes might
further help in understanding the role of this triplet repeat in
varying manifestation of androgen insensitivity. The
residual AR function in AR knockout mice might depend
upon the type of mutation and also the number of CAG
repeats in the background of the mutation. Therefore,
knockout studies might further assist in understanding
the effect of coding triplet repeats on AR function.
To conclude, CAG repeat probably functions as a
low penetrance allele for androgen sensitivity, whereas
GGN repeat length does not seem to affect the same. In
molecular defects resulting in a partial loss of androgen
sensitivity, the presence of a less than average number
of CAG repeats in background might partially
compensate for the phenotypic effect, while CAG repeat lengths
above average might enunciate the extent of androgen
insensitivity. However, the number of CAG repeats does
not seem to have any effect in combination with molecular defects resulting in complete loss of androgen
sensitivity. The penetrance of CAG repeats might
further vary between populations depending upon the
combinations from other polymorphisms in AR and its
interacting genes, somatic mosaicism in AR gene in
androgen target tissues, ethnic origin and normal CAG repeat
range in the population. Undoubtedly, the level of
androgen insensitivity will be grossly determined by type and
site of molecular defect, but it will be fine-tuned by CAG
repeat allele and other polymorphisms in AR and its
interacting genes. Taking into consideration the
importance of CAG repeats, we recommend CAG repeat length
analysis in all the studies on AR gene in human subjects.
Analysis of AR gene for CAG repeat length,
AR somatic mosaicism, and pubertal hormone levels to calculate
overall ASI will help in appropriate management of androgen
insensitivity cases.
Acknowledgment
Financial support of Council of Scientific and
Industrial Research, and Indian Council of Medical
Research, Government of India, New Delhi is
gratefully acknowledged.
References
1 Quigley CA, De Bellis A, Marschke KB, el-Awady MK,
Wilson EM, French FS. Androgen receptor defects: historical,
clinical, and molecular perspectives. Endocr Rev 1995; 16:
271_321.
2 Mebarki F, Forest MG, Josso N, Bertrand AM, David M,
Chatelain P, et al. Complete direct sequencing of the entire
AR gene in 45 unrelated patients with androgen insensitivity
syndrome: mutations identified in 32 patients (18 novel
mutations), no mutation detected in 13 other patients (29%).
Am J Hum Genet 1994; 55: 231.
3 Batch JA, Williams DM, Davies HR, Brown BD, Evans BA,
Hughes IA, et al. Androgen receptor gene mutations identified
by SSCP in fourteen subjects with androgen insensitivity
syndrome. Hum Mol Genet 1992; 1: 497_503.
4 Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen
receptor gene mutations database (ARDB): 2004 update. Hum
Mutat 2004; 23: 527_33.
5 Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K.
Inherited and de novo androgen receptor gene mutations:
investigation of single-case families. J Pediatr 1998; 132:
939_43.
6 Ris-Stalpers C, Trifiro MA, Kuiper GG, Jenster G, Romalo
G, Sai T, et al. Substitution of aspartic acid-686 by histidine
or asparagine in the human androgen receptor leads to a
functionally inactive protein with altered hormone-binding
characteristics. Mol Endocrinol 1991; 5: 1562_9.
7 Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse
K. The clinical and molecular spectrum of androgen
insensitivity syndromes. Am J Med Genet 1996; 63: 218_22.
8 MacLean HE, Ball EM, Rekaris G, Warne GL, Zajac JD. Novel
androgen receptor gene mutations in Australian patients with
complete androgen insensitivity syndrome. Hum Mutat 2004;
23: 287.
9 Nordenskjold A, Soderhall S. An androgen receptor gene
mutation (A645D) in a boy with a normal phenotype. Hum
Mutat 1998; 11: 339.
10 Wang Q, Ghadessy FJ, Yong EL. Analysis of the transactivation
domain of the androgen receptor in patients with male
infertility. Clin Genet 1998; 54: 185_92.
11 Gottlieb B, Vasiliou DM, Lumbroso R, Beitel LK, Pinsky L,
Trifiro MA. Analysis of exon 1 mutations in the androgen
receptor gene. Hum Mutat 1999; 14: 527_39.
12 Batch JA, Williams DM, Davies HR, Brown BD, Evans BA,
Hughes IA, et al. Androgen receptor gene mutations identified
by SSCP in fourteen subjects with androgen insensitivity
syndrome. Hum Mol Genet 1992; 1: 497_503.
13 Yong EL, Tut TG, Ghadessy FJ, Prins G, Ratnam SS. Partial
androgen insensitivity and correlations with the predicted three
dimensional structure of the androgen receptor ligand-binding
domain. Mol Cell Endocrinol 1998; 137: 41_50.
14 Gottlieb B, Beitel LK, Trifiro MA. Somatic mosaicism and
variable expressivity. Trends Genet 2001; 17: 79_82.
15 Gottlieb B, Beitel LK, Trifiro MA. Variable expressivity and
mutation databases: The androgen receptor gene mutations
database. Hum Mutat 2001; 17: 382_8.
16 Holterhus PM, Sinnecker GH, Hiort O. Phenotypic diversity
and testosterone-induced normalization of mutant L712F
androgen receptor function in a kindred with androgen
insensitivity. J Clin Endocrinol Metab 2000; 85: 3245_50.
17 Boehmer AL, Brinkmann AO, Nijman RM, Verleun-Mooijman
MC, de Ruiter P, Niermeijer MF, et al. Phenotypic variation
in a family with partial androgen insensitivity syndrome
explained by differences in 5alpha dihydrotestosterone
availability. J Clin Endocrinol Metab 2001; 86: 1240_6.
18 Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity
of mutations in androgen receptor gene. Asian J Androl 2007;
9: 147_79.
19 Chamberlain NL, Driver ED, Miesfeld RL. The length and
location of CAG trinucleotide repeats in the androgen
receptor N-terminal domain affect transactivation function. Nucleic
Acids Res 1994; 22: 3181_6.
20 Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a
repressive function of the long polyglutamine tract in the human
androgen receptor: possible pathogenetic relevance for the
(CAG)n-expanded neuronopathies. Hum Mol Genet
1995; 4: 523_7.
21 Thangaraj K, Joshi MB, Reddy AG, Gupta NJ, Chakravarty
B, Singh L. CAG repeat expansion in the androgen receptor
gene is not associated with male infertility in Indian populations.
J Androl 2002; 23: 813_6.
22 Singh R, Shastry PK, Rasalkar AA, Singh L, Thangaraj K. A
novel androgen receptor mutation resulting in complete
androgen insensitivity syndrome and bilateral Leydig cell hyperplasia.
J Androl 2006; 27: 510_6.
23 Heinlein CA, Chang C. Androgen receptor in prostate cancer.
Endocr Rev 2004; 25: 276_308.
|